ROCHESTER, Minn. — New research from Mayo Clinic finds that patients with lymphedema —swelling of the limbs caused by the accumulation of protein-rich fluids of the immune system — had twice the risk of developing skin cancer than patients without lymphedema. Patients with lymphedema had a significantly higher frequency of developing basal cell carcinomas and squamous cell...
Latest News
ROCHESTER, Minn. — Researchers have discovered a novel molecular path that predisposes patients to develop primary biliary cirrhosis, a disease that mainly affects women and slowly destroys their livers. Primary biliary cirrhosis has no known cause. The finding, significant because it is a first step toward developing a targeted treatment...
Montreal, Quebec – A new study from a team of McGill University and Vanderbilt University researchers is shedding light on our understanding of the molecular origins of some forms of autism and intellectual disability. For the first time, researchers were able to successfully capture atomic resolution images of the fast-moving ionotropic...
Montreal, Canada – A new technique developed by McGill researchers for mechanically manipulating stem cells could lead to new stem cell treatments, which have yet to fulfill their therapeutic potential. Stem cell therapy has been heralded as a new way to treat many diseases, ranging from multiple sclerosis, Alzheimer’s and...
Montreal, Canada – The gut microbiome, an ecosystem of trillions of microorganisms in the human digestive tract, has been increasingly linked to chronic diseases. Research led by Dr. Connor Prosty and his team at McGill University consolidates recent findings that demonstrate a causal role for the gut microbiome in the...
HOUSTON and SOUTH SAN FRANCISCO, Calif. ― The University of Texas MD Anderson Cancer Center and Rigel Pharmaceuticals, Inc. today announced a multi-year strategic development collaboration to expand the evaluation of olutasidenib in acute myeloid leukemia (AML) and other hematologic cancers. The alliance brings together MD Anderson’s clinical research expertise with...
HOUSTON, Texas and MIAMI, Florida ― The University of Texas MD Anderson Cancer Center and Summit Therapeutics, Inc. today announced a strategic five-year collaboration agreement for the purpose of accelerating the development of ivonescimab. Leveraging MD Anderson’s clinical infrastructure and research expertise together with Summit’s innovative, investigational, potential first-in-class PD-1/VEGF...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Clinical advances include positive data with targeted therapies for HER2 exon 20 mutant lung cancer, for older patients with mantle cell lymphoma...
HOUSTON ― The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. Recent developments at...
SAN DIEGO, CA ― The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. This...